The conversation around psilocybin is undergoing a radical shift. For decades, we viewed this compound almost exclusively through the lens of psychology—mood, trauma, and “ego dissolution.” But a landmark 2025 study has revealed that psilocybin’s most profound potential might not be in the mind, but in the metabolic engine of the body.
In research led by the Universities of Padua and Milan and published in Pharmacological Research (2025), scientists discovered that ultra-low, non-psychedelic doses of psilocybin can effectively “reset” metabolic health in subjects suffering from obesity and fatty liver disease.
The researchers used a common model for modern metabolic syndrome: mice fed a high-fat, high-fructose diet. These “overfed” subjects developed significant weight gain, insulin resistance, and fatty liver disease (MASLD).
Typically, psilocybin is studied for its interaction with the 5-HT2A receptor—the part of the brain responsible for psychedelic experiences. However, this study uncovered a completely different pathway. At chronic, low doses, psilocybin targeted the 5-HT2B receptor located in the liver and muscles.
The Results after 12 Weeks:
If all that talk about receptors and lipidomes sounds like a different language, here is the simplified version of what this research means for the future of wellness:
Think of your body like a car that has been running on the wrong fuel for years.
1. The Sludge: If you eat a modern diet high in fats and sugars, your “engine” (your liver) gets gummed up with a kind of metabolic sludge. This makes the whole car run poorly, leading to weight gain and sluggishness.
2. The Reset Button: This research suggests that low doses of psilocybin act like a specialized engine cleaner. It doesn’t affect the “driver” (your conscious mind), so you don’t feel high. Instead, it goes straight to the engine parts.
3. The Result: It helps the liver flush out that sludge and makes your muscles better at using fuel. Essentially, it helps the body remember how to be healthy again.
When reading lab studies, it’s easy to wonder if the dose is realistic for humans. Thanks to Human Equivalent Dose (HED) scaling, we can translate the mouse data into real-world terms.
How does that compare to a standard microdose?
A typical microdose is usually defined as $0.1$ mg to $0.3$ mg of pure psilocybin. This means the “metabolic reset” seen in the study was achieved using the exact range many microdosers already use for focus and mood.
It is important to emphasize that while these findings are a breakthrough, this research is still in its preclinical phase. What does that mean? It means that while the results in mice are incredibly promising and provide a clear biological “roadmap,” we are still awaiting the results of large-scale human clinical trials to confirm these exact metabolic effects in people.
We are entering a new era where psilocybin is viewed as a systemic modulator. It’s no longer just about “fixing the mind”; it’s about repairing the biological foundation upon which the mind sits.
Colognesi, M., Gabbia, D., et al. (2025). Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and Type 2 Diabetes via 5-HT2B receptor-dependent mechanisms. Pharmacological Research, 224:108080.
You must be 18+ to visit this website. Confirm this below.
You've unlocked a
What do you want most from microdosing?
One more step
We'll send the guide and point you to the section that matches your goal.
Your Transformation Guide is on its way to . Not there in a few minutes? Check spam and drag us into your primary inbox.
